research Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
Search
for
Sort by
Research
540-570 / 1000+ results 
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Patient-Reported Flare Symptoms Following COVID-19 Vaccination in Systemic Lupus Erythematosus
COVID-19 vaccines are generally safe for people with lupus, though some may experience mild flare symptoms.
research Safety of dermatologic medications in pregnancy and lactation
Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
research Застосування кріоконсервованої плаценти в комплексному лікуванні флегмон щелепно-лицевої локалізації
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research Modified phenol peels for treatment‐refractory hyperpigmentation of lichen planus pigmentosus: A retrospective clinico‐dermoscopic analysis
Modified phenol peels effectively reduced stubborn skin pigmentation in patients with Lichen Planus Pigmentosus.
research ADVANCES IN PSORIASIS THERAPY
New psoriasis treatments are effective but come with side effects and risks.
research BCG'osis
A three-year-old girl survived a rare serious infection caused by BCG vaccination, which improved after treatment with a leprosy drug.
research Farmácia Beleza, Matosinhos e Serviços Farmacêuticos do Cittadella Hospital - ULSS 6 Euganea, Itália
Pharmacists play a crucial role in patient care and education.
research Covid-19 in Lupus Nephritis
Patients with lupus nephritis and COVID-19 can improve with proper treatment.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
Talquetamab may cause hair loss and skin issues.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Differential cardiometabolic outcomes of leuprolide versus spironolactone in women with polycystic ovary syndrome
Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Lactium: A Novel Drug for Psychocutaneous Skin Disorders
Lactium, a milk protein, can help reduce symptoms of skin disorders linked to stress and anxiety without side effects.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
research Oral calcitriol in the treatment of scleroderma 'en coupe de sabre'
Oral calcitriol helped improve scleroderma and hair regrowth in a young woman.
research Case Report: Bimekizumab for dissecting cellulitis of the scalp
Bimekizumab effectively treats scalp cellulitis and improves quality of life.
research Genome-Wide Association Studies for Immunoglobulin Concentrations in Colostrum and Serum in Chinese Holstein
Certain genes influence immunoglobulin levels in Chinese Holstein cows, which can improve calf health.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.